IMJUDO

Google image searchProduct monograph

Active ingredient

tremelimumab, 20 MG/ML

DIN: 02541009

Dosage form(s): SOLUTION

Route(s) of administration: INTRAVENOUS

Schedule: Prescription

Company: ASTRAZENECA CANADA INC

Date: 23-OCT-2023

ATC:

• L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
• L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
• L01FX — Other monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
• L01FX20 — TREMELIMUMAB (ATC/DDD)

Pharmaceutical standard: MFR

External Links for Imjudo

Search on Google

• Imjudo side effects
• Imjudo dosage
• tremelimumab side effects
• tremelimumab dosage

Astrazeneca Canada Inc

Go to AstraZeneca website to see drug product details. Sometimes you can find imjudo photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.